Navigation Links
Curemark Awarded Qualifying Therapeutic Discovery Project (QTDP) Grant
Date:11/2/2010

RYE, N.Y., Nov. 2, 2010 /PRNewswire/ -- Curemark LLC, a drug research and development company focused on the treatment of neurological diseases, announced today that it has been awarded a grant by the United States government under the Qualifying Therapeutic Discovery Project (QTDP) Program to advance the development of its lead product CM-AT for autism.  CM-AT is presently in Phase III clinical trials at 18 sites around the US.

The QTDP grant program provides support for innovative projects that are determined by the U.S. Department of Health and Human Services to have reasonable potential to result in a new therapy, reduce health care costs, or significantly advance the goal of curing cancer. The QTDP program was created by Congress on May 21, 2010 under Section 48D of the Internal Revenue Code, as enacted under the Patient Protection and Affordable Care Act.

Dr. Joan Fallon, Curemark CEO, commented: "We are very appreciative of the recognition and support provided by this award for CM-AT that has the potential to treat the symptoms of autism, and also provide significant economic benefits to our community."

CM-AT, Curemark's autism treatment, targets enzyme deficiencies in autistic children that affect the availability of amino acids, the building blocks of chemicals essential for brain function. The company is currently conducting Phase III CM-AT trials at 18 sites nationwide with a planned total of 170 children. If approved, CM-AT, which has been granted Fast Track status from the FDA, will be one of the first therapies to address the underlying physiology of autism.

About CUREMARK LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com

Safe Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.


'/>"/>
SOURCE Curemark LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Curemark Appoints Preeminent Pediatrics Gastroenterologist
2. Curemark Closes Series A Financing
3. Curemark CEO Presents at Epigenomics Conference
4. Curemark Announces Senior Executive Promotions
5. Curemark Enrolls First Patients in Phase III Clinical Trials for Autism Treatment
6. Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites
7. Curemark Opens Patient Enrollment for Autism Treatment at Three More Clinical Trial Sites
8. Curemark CM-AT Autism Treatment Granted FDA Fast Track Status
9. Curemark Adds UC Davis MIND Institute to Autism Clinical Trial Sites
10. Dr. Joan Fallon, Curemark CEO, Addresses Keystone Symposia Meeting On Autism
11. Curemark Begins Autism Trials at Two More Sites
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... , May 24, 2016 ... médica para ayudar a los médicos a compartir sus ... pacientes a escala mundial. Profesionales médicos de Europa, África, ... se han apuntado a la aplicación, que combina la ... un entorno totalmente seguro. Educación   ...
(Date:5/24/2016)... 24, 2016  NxStage Medical, Inc. (Nasdaq: ... advancing renal care, today announced that Jeffrey H. ... the following schedule of investor conferences. Where applicable, a ... http://ir.nxstage.com/ .   ... NY, NY           Friday, June 10, 2016 1:30 p.m. ...
(Date:5/24/2016)... HONG KONG , May 24, 2016 ... de COMBO ™ , la ... présentent des cathéters destinés à l,intervention portant ... artério-veineuse (FAV)   OrbusNeich, entreprise ... vasculaires permettant de changer la vie, a ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... ... provide strategic sales leadership and to further develop their rapidly expanding portfolio of ... Business Administration with a concentration in Marketing and an M.B.A. with concentration in ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... safety efforts for several years, and the efforts have paid off. Since ... include new standards of care to enhance perioperative patient experiences and reduce costly ...
(Date:5/26/2016)... Las Vegas, NV (PRWEB) , ... May 26, 2016 , ... ... of Ergonomic Tools,” identifies the impact of mobile devices on the billions of users, ... upper backs and necks. While not life threatening, the frequent and common action ...
(Date:5/26/2016)... ... May 26, 2016 , ... RadSite™, ... serve on its Accreditation and Standards Committees and support the organization’s quality ... key process and outcome measures, with the ultimate mission of improving image ...
(Date:5/26/2016)... ... May 26, 2016 , ... In 1980, Bill Howe opened AM/PM ... the beach community. His vision to grow the company was built on a simple ... the highest level of training and customer service. Over 35 years later, Bill Howe ...
Breaking Medicine News(10 mins):